HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Risk Panel DXM Meeting Raises Stakes on Age Restriction Movement

This article was originally published in The Tan Sheet

Executive Summary

A Drug Safety and Risk Management Advisory Committee meeting scheduled for Sept. 14 on the potential for abuse of the cough suppressant dextromethorphan could bring the OTC industry's next regulatory nightmare

You may also be interested in...

FDA Panel Says Leave DXM Unscheduled For Now, Urges Congressional Action

Dextromethorphan likely will escape scheduling as a controlled substance in the near term, but manufacturers and lawmakers should push efforts to curb abuse to keep the cough suppressant available OTC in the long run

NDAC Veterans Join DSaRM Advisory Panel For DXM Safety Meeting

The presence of Nonprescription Drug Advisory Committee members as temporary voters on FDA's Drug Safety and Risk Management Advisory Committee brings expertise on OTC issues and a potential industry advocate to the Sept. 14 meeting on dextromethorphan abuse

FDA Panel To Weigh DXM Education, Sales Restrictions Against Scheduling

The continued availability of OTC dextromethorphan depends on convincing safety experts that less restrictive measures than scheduling DXM as a controlled substance will sufficiently reduce abuse

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts